David Saxon

“And congratulations on the roles, Warren and Deborah. Maybe just on the, I'll start on the ERP. Any way to quantify the impact to the second quarter earnings, I'm sorry, orders or revenue?”

“First on contact lenses, maybe if you could peel back the onion there, like how much of contact lens growth was price versus volume, and then any way to break out the legacy volume decline versus the core volume growth, and how you're just thinking about the market's ability to take price in the back half and into 27.”

“Maybe I'll just keep it to one given the time. So, and higher level too. So, just when you're thinking about Invista's overall margin improvement potential, just curious where you see the most opportunity across SP&T and ENC.”

“And then maybe for Mike, just regarding the DRG changes, I mean, is that something you could start to see a benefit from in terms of just starting those conversations and getting access into those centers even before it goes live?”

“I wanted to follow up on the case volume growth assumption, the high teens and the back half versus 20% in the first half. So I guess to actually slow down, what's driving that?”